Single-dose intravenous iron for iron deficiency: a new paradigm

Hematology. American Society of Hematology. Education Program - Tập 2016 Số 1 - Trang 57-66 - 2016
Michael Auerbach1,2, Thomas G. DeLoughery3,4
1Clinical Professor of Medicine, Georgetown University School of Medicine, Washington, DC; and
2Private practice, Baltimore, Md
3Department of Hematology and Medical Oncology, Division of Laboratory Medicine, and
4Department of Pathology, Oregon Health Sciences University, Portland, OR

Tóm tắt

AbstractIron-deficiency anemia is the most common hematologic problem in the world. Although oral iron is often viewed as front-line therapy, extensive published evidence has accumulated that IV iron is superior, in both efficacy and safety, to oral iron in many clinical situations and should be introduced much sooner in the treatment paradigm of iron-deficient patients. In this chapter, we will review the formulations of IV iron that allow total complete replacement doses in 1 or 2 sessions including practical tips for administration. We realize safety concerns abound and therefore will analyze evidence based overstated concerns regarding serious adverse events highlighting unnecessary interventions for minor, self-limiting infusion reactions, which infrequently occur with intravenous iron administration. Recent data for the use of IV iron in a variety of clinic situations will be reviewed including women with heavy uterine bleeding, pregnancy, bariatric surgery, inflammatory bowel disease, and restless legs syndrome. Briefly discussed is the new frontier of IV iron’s use in the prevention of acute (high altitude) mountain sickness. It is clear that in many clinical situations IV iron is a new and improved standard of care offering advantages over oral iron in efficacy, toxicity, and convenience to patients and health care providers.

Từ khóa


Tài liệu tham khảo

Gasche, 2007, Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases, Inflamm Bowel Dis, 13, 1545, 10.1002/ibd.20285

Jimenez, 2016, On both sides of the ocean, Blood Transfus (Italy)

Tolkien, 2015, Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis, PLoS One, 10, e0117383, 10.1371/journal.pone.0117383

Schrier, 2016, Treatment of Anemia due to iron deficiency

Allen, 2011, Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial, Sleep Med, 12, 906, 10.1016/j.sleep.2011.06.009

Ondo, 2010, Intravenous iron dextran for severe refractory restless legs syndrome, Sleep Med, 11, 494, 10.1016/j.sleep.2009.12.002

Talbot, 2011, Intravenous iron supplementation may protect against acute mountain sickness: a randomized, double-blinded, placebo-controlled trial, High Alt Med Biol, 12, 265, 10.1089/ham.2011.1005

Gafter-Gvili, 2014, Should the ASCO/ASH Guidelines for the use of intravenous iron in cancer- and chemotherapy-induced anemia be updated?, J Natl Compr Canc Netw, 12, 657, 10.6004/jnccn.2014.0069

Wysowski, 2010, Use of parenteral iron products and serious anaphylactic-type reactions, Am J Hematol, 85, 650, 10.1002/ajh.21794

Auerbach, 2016, How we diagnose and treat iron deficiency anemia, Am J Hematol, 91, 31, 10.1002/ajh.24201

Baird, 1954, Intramuscular iron therapy in iron-deficiency anaemia, Lancet, 267, 942, 10.1016/S0140-6736(54)92555-6

Auerbach, 2008, Intravenous iron: from anathema to standard of care, Am J Hematol, 83, 580, 10.1002/ajh.21154

Kanakaraddi, 1973, Comparative therapeutic study of T.D.I. and I.M. injections of iron dextran complex in anaemia, J Assoc Physicians India, 21, 849

Varde, 1964, Treatment of 300 cases of iron deficiency of pregnancy by total dose infusion of iron-dextran complex, J Obstet Gynaecol Br Commonw, 71, 919, 10.1111/j.1471-0528.1964.tb04380.x

Marchasin, 1964, The treatment of iron-deficiency anemia with intravenous iron dextran, Blood, 23, 354, 10.1182/blood.V23.3.354.354

Hamstra, 1980, Intravenous iron dextran in clinical medicine, JAMA, 243, 1726, 10.1001/jama.1980.03300430028018

Eschbach, 1989, Treatment of the anemia of progressive renal failure with recombinant human erythropoietin, N Engl J Med, 321, 158, 10.1056/NEJM198907203210305

Fishbane, 1995, Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation, Am J Kidney Dis, 26, 41, 10.1016/0272-6386(95)90151-5

Michael, 2002, Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran, Kidney Int, 61, 1830, 10.1046/j.1523-1755.2002.00314.x

Chertow, 2006, Update on adverse drug events associated with parenteral iron, Nephrol Dial Transplant, 21, 378, 10.1093/ndt/gfi253

Sav, 2007, Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran?, Ren Fail, 29, 423, 10.1080/08860220701278208

Moniem, 2007, Tolerability and efficacy of parenteral iron therapy in hemodialysis patients, a comparison of preparations, Transfus Altern Transfus Med, 9, 37, 10.1111/j.1778-428X.2007.00050.x

Critchley, 2007, Adverse events associated with intravenous iron infusion (low-molecular-weight iron dextran and iron sucrose): A systematic review, Transfus Altern Transfus Med, 9, 8, 10.1111/j.1778-428X.2007.00042.x

Macdougall, 2014, A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD, Clin J Am Soc Nephrol, 9, 705, 10.2215/CJN.05320513

Okam, 2012, Comparative rates of adverse events with different formulations of intravenous iron, Am J Hematol, 87, E123, 10.1002/ajh.23322

Avni, 2015, The safety of intravenous iron preparations: systematic review and meta-analysis, Mayo Clin Proc, 90, 12, 10.1016/j.mayocp.2014.10.007

Wang, 2015, Comparative risk of anaphylactic reactions associated with intravenous iron products, JAMA, 314, 2062, 10.1001/jama.2015.15572

DeLoughery, 2016, Is low-molecular weight iron dextran really the most risky iron?-Unconvincing data from an unconvincing study, Am J Hematol, 91, 451, 10.1002/ajh.24326

Macdougall, 2016, Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference, Kidney Int, 89, 28, 10.1016/j.kint.2015.10.002

Barton, 2000, Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation, Am J Med, 109, 27, 10.1016/S0002-9343(00)00396-X

Auerbach, 2015, On the safety of intravenous iron, evidence trumps conjecture, Haematologica, 100, e214, 10.3324/haematol.2014.121004

Andrews, 1999, Disorders of iron metabolism, 10.1056/NEJM199912233412607

Auerbach, 2011, Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia, Am J Hematol, 86, 860, 10.1002/ajh.22153

Auerbach, 2007, Clinical update: intravenous iron for anaemia, Lancet, 369, 1502, 10.1016/S0140-6736(07)60689-8

Auerbach, 2010, Clinical use of intravenous iron: administration, efficacy and safety, Hematol Am Soc Hematol Educ Program, 338

Rampton, 2014, Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management, Haematologica, 99, 1671, 10.3324/haematol.2014.111492

Rosner, 2011, Ferumoxytol for the treatment of iron deficiency, Expert Rev Hematol, 4, 399, 10.1586/ehm.11.31

Jahn, 2011, A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications, Eur J Pharm Biopharm, 78, 480, 10.1016/j.ejpb.2011.03.016

Bircher, 2014, Hypersensitivity from intravenous iron products, Immunol Allergy Clin North Am, 34, 707, 10.1016/j.iac.2014.04.013

Auerbach, 2013, Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min, Am J Hematol, 88, 944, 10.1002/ajh.23534

Mani, 2010, Severe hypophosphatemia after intravenous administration of iron carboxymaltose in a stable renal transplant recipient, Transplantation, 90, 804, 10.1097/TP.0b013e3181f00a18

Steinmetz, 2013, Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia, Ann Oncol, 24, 475, 10.1093/annonc/mds338

Evstatiev, 2011, FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease, Gastroenterology, 141, 846, 10.1053/j.gastro.2011.06.005

Van Wyck, 2009, Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial, Transfusion, 49, 2719, 10.1111/j.1537-2995.2009.02327.x

Myers, 2012, Comparative efficacy and safety of intravenous ferric carboxymaltose (Ferinject) and iron(III) hydroxide dextran (Cosmofer) in pregnancy, Obstet Med, 5, 105, 10.1258/om.2012.110095

Muñoz, 2014, Very-short-term perioperative intravenous iron administration and postoperative outcome in major orthopedic surgery: a pooled analysis of observational data from 2547 patients, Transfusion, 54, 289, 10.1111/trf.12195

Kalra, 2016, Efficacy and safety of iron isomaltoside (Monofer(®)) in the management of patients with iron deficiency anemia, Int J Nephrol Renovasc Dis, 9, 53, 10.2147/IJNRD.S89704

Congdon, 2012, Iron deficiency in infancy is associated with altered neural correlates of recognition memory at 10 years, J Pediatr, 160, 1027, 10.1016/j.jpeds.2011.12.011

Chang, 2013, Effect of iron deficiency anemia in pregnancy on child mental development in rural China, Pediatrics, 131, e755, 10.1542/peds.2011-3513

Reveiz, 2012, Treatments for iron-deficiency aneaemia in pregnancy. The Cochrane Collaboration

Hanieh, 2013, The effect of intermittent antenatal iron supplementation on maternal and infant outcomes in rural Viet Nam: a cluster randomised trial, PLoS Med, 10, e1001470, 10.1371/journal.pmed.1001470

Ayub, 2008, Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy, J Coll Physicians Surg Pak, 18, 424

Christoph, 2012, Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose, J Perinat Med, 40, 469, 10.1515/jpm-2011-0231

Wong, 2016, Safety and efficacy of rapid (1,000 mg in 1 hr) intravenous iron dextran for treatment of maternal iron deficient anemia of pregnancy, Am J Hematol, 91, 590, 10.1002/ajh.24361

Salgado, 2014, Anemia and iron deficiency before and after bariatric surgery, Surg Obes Relat Dis, 10, 49, 10.1016/j.soard.2013.06.012

Obinwanne, 2014, Incidence, treatment, and outcomes of iron deficiency after laparoscopic Roux-en-Y gastric bypass: a 10-year analysis, J Am Coll Surg, 218, 246, 10.1016/j.jamcollsurg.2013.10.023

Muñoz, 2009, Iron deficiency and anaemia in bariatric surgical patients: causes, diagnosis and proper management, Nutr Hosp, 24, 640

Malone, 2013, Comparative review of the safety and efficacy of ferric carboxymaltose versus standard medical care for the treatment of iron deficiency anemia in bariatric and gastric surgery patients, Obes Surg, 23, 1413, 10.1007/s11695-013-0939-6

Strauss, 2013

Gasche, 2004, Iron, anaemia, and inflammatory bowel diseases, Gut, 53, 1190, 10.1136/gut.2003.035758

Erichsen, 2005, Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease, Scand J Gastroenterol, 40, 1058, 10.1080/00365520510023198

Lee, 2016, Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD, Gut, gutjnl-2015-309940

Kulnigg, 2008, A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial, Am J Gastroenterol, 103, 1182, 10.1111/j.1572-0241.2007.01744.x

Teitelbaum, 2016, Nutritional deficiencies in inflammatory bowel disease

García-López, 2016, High-dose intravenous treatment in iron deficiency anemia in inflammatory bowel disease: early efficacy and impact on quality of life, Blood Transfus, 14, 199

Allen, 2005, Restless legs syndrome prevalence and impact: REST general population study, Arch Intern Med, 165, 1286, 10.1001/archinte.165.11.1286

Allen, 2001, MRI measurement of brain iron in patients with restless legs syndrome, Neurology, 56, 263, 10.1212/WNL.56.2.263

Rizzo, 2013, Low brain iron content in idiopathic restless legs syndrome patients detected by phase imaging, Mov Disord, 28, 1886, 10.1002/mds.25576

Sun, 1998, Iron and the restless legs syndrome, Sleep, 21, 371, 10.1093/sleep/21.4.381

Mehmood, 2014, Response to intravenous iron in patients with iron deficiency anemia (IDA) and restless leg syndrome (Willis-Ekbom disease), Sleep Med, 15, 1473, 10.1016/j.sleep.2014.08.012

Camaschella, 2013, The Ham Wasserman Lecture. Iron and hepcidin: a story of recycling and balance, Hematology Am Soc Hematol Educ Program, 1

Smith, 2008, The increase in pulmonary arterial pressure caused by hypoxia depends on iron status, J Physiol, 586, 5999, 10.1113/jphysiol.2008.160960

Thông tin
Thông tin xuất bản

Hematology. American Society of Hematology. Education Program

Tập 2016 Số 1

57-66

Thông tin tác giả